Barclays Downgrades GlaxoSmithKline (GSK) to Equal Weight

Barclays downgraded shares of GlaxoSmithKline (LON:GSK) to an equal weight rating in a report issued on Tuesday, MarketBeat.com reports. They currently have GBX 1,600 ($20.91) price objective on the stock, down from their prior price objective of GBX 1,750 ($22.87).

A number of other brokerages have also recently issued reports on GSK. Shore Capital reiterated a buy rating on shares of GlaxoSmithKline in a report on Tuesday, August 7th. Liberum Capital reiterated a buy rating on shares of GlaxoSmithKline in a report on Tuesday, August 7th. Goldman Sachs Group set a GBX 1,900 ($24.83) price objective on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Wednesday, August 15th. Jefferies Financial Group set a GBX 1,775 ($23.19) price objective on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Thursday, August 16th. Finally, JPMorgan Chase & Co. reiterated a neutral rating and issued a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline in a report on Tuesday, August 21st. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of GBX 1,512.99 ($19.77).

GlaxoSmithKline stock opened at GBX 1,437.40 ($18.78) on Tuesday. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($16.14) and a 12 month high of GBX 1,724.50 ($22.53).

The company also recently announced a dividend, which will be paid on Thursday, January 10th. Shareholders of record on Thursday, November 15th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.26%. The ex-dividend date of this dividend is Thursday, November 15th.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: What factors cause inflation to rise?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply